Ivermectin use for COVID-19 treatment to be studied with a randomised clinical trial in El Paso and New Mexico

People infected with COVID-19, who are eligible to partake in a study, could be given Ivermectin to treat the infectious disease.

Texas Tech University Health Sciences Center El Paso is part of a nationwide study to research potential treatments for those suffering from the virus.

TTUHSC El Paso Part announced it will conduct two studies: The first project, ACTIV-6, is a national trial to evaluate repurposed drugs to see if they can be effective in treating COVID-19.

Michelson’s study will determine if the drug can be used to treat COVID-19 patients.

TTUHSC El Paso was recently awarded a $1.7 million grant from the National Institutes of Health as part of a multi-center effort to test treatments on COVID-19 patients.

Michelson is leading the effort at TTUHSC El Paso on the two research projects.

During the trial, half the patients will receive the drug, and the other half will receive a placebo. Neither the physician nor the patient will know which one the patient receives.

ACTIV-6 Trial

With the help of various universities, including TTUHSC El Paso, the ACTIV-6 trial will test several drugs – which have been approved by the FDA for other illnesses – to see if they can be used to treat COVID-19 patients. The study will focus on patients who do not have to be hospitalized. Patients throughout El Paso and southern New Mexico will be eligible to join.

Michelson hopes to begin enrolling patients in ACTIV-6 trial within the next month.

Nationally, the NIH aims to enroll 15,000 patients, but in El Paso the goal is to recruit 400. Michelson hopes to recruit patients from the entire Borderland region, including Las Cruces.

[link to kfoxtv.com (secure)]